Clinical trials: Stage IIIA Non-small Cell Lung Cancer
Lung Cancer
Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer
RATIONALE: Imaging procedures, such as positron emission tomography (PET) scan and CT scan, may help doctors plan radiation therapy for patients with non-small cell lung cancer.
- Trial name
- NCT00310219
- Testing
- computed tomography, positron emission tomography
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00450281
- Testing
- chromogenic in situ hybridization, gene expression analysis, mutation analysis
- Where
- 405 sites in United States
- Volunteers
- 981 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage…
- Trial name
- NCT00019929
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081302
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung
Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung squamous cell carcinoma has a better tumor response rate and safety, therefore.The main purpose of this study is to observe the safety and…
- Trial name
- NCT01872403
- Testing
- nanoparticle albumin-bound paclitaxel/carboplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Locally Advanced Non Small-Cell Lung Canger
Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer
Nitroglycerin will increase the effectiveness of treatment with induction chemotherapy and concurrent chemo-radiotherapy by reducing chemo-radio resistance through an increased oxygen pressure in tumoral tissue.
- Trial name
- NCT00886405
- Testing
- Transdermal nitroglycerin
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- National Institute of Cancerología
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
- Trial name
- NCT06394427
- Testing
- cycles of neoadjuvant therapy and duration of waiting for surgery
- Volunteers
- 250 people
- Sponsor
- West China Hospital
Non Small Cell Lung Cancer, Stage IIIA Lung Cancer
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.
- Conditions
- Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
- Trial name
- ATHENEA (NCT07153445)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 21 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion.
- Trial name
- NCT05241028
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hebei Medical University Fourth Hospital
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
ALK Gene Mutation, BRAF Gene Mutation
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell…
- Conditions
- ALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03049618
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
Non-small Cell Lung Cancer, Neoadjuvant Therapy
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy
- Trial name
- NCT06065813
- Testing
- Toripalimab, Conventional segmental radiotherapy, opreation
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northern Jiangsu People's Hospital
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00032032
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 51 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)
RATIONALE: Collecting and storing samples of blood and exhaled breath from patients with cancer and from healthy participants to study in the laboratory may help doctors learn more about changes that occur in DNA and identify…
- Trial name
- NCT00898209
- Testing
- protein expression analysis, proteomic profiling, biologic sample preservation procedure
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of methoxyamine when given together with pemetrexed disodium, cisplatin, and radiation therapy in treating patients with stage IIIA-IV non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02535325
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Neoplasms, Lung Cancer
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection.
- Conditions
- Lung Neoplasms, Lung Cancer, Nonsmall Cell Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT03838588
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Geneplus-Beijing Co. Ltd.